Ocular pharmacology in the treatment of vitreous, retina and choroid diseases;Farmacologia ocular aplicada no tratamento de doenças do vítreo, retina e coróide

Arquivos Brasileiros de Oftalmologia

Volumn 73, Issue 3, 2010, Pages 294-299

  De Arruda Mello Filho, Paulo Augusto ^a   Maia, Maurício ^a   Rodrigues, Eduardo Buchelle ^a   Farah, Michel Eid ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Choroidal diseases drug therapy; Coloring agents; Drug delivery systems; Eye diseases drug therapy; Retinal diseases drug therapy; Vitrectomy

Indexed keywords

DRUG; EYE DROPS;

ARTICLE; CHOROID DISEASE; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; EYE DISEASE; HUMAN; RETINA DISEASE; VITREOUS BODY;

CHOROID DISEASES; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; EYE DISEASES; HUMANS; OPHTHALMIC SOLUTIONS; PHARMACEUTICAL PREPARATIONS; RETINAL DISEASES; VITREOUS BODY;

EID: 78449239619     PISSN: 00042749     EISSN: 16782925     Source Type: Journal    
DOI: 10.1590/S0004-27492010000300018     Document Type: Article

References (40)

1. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005; 36(4):331-5. Comment in: Ophthalmic Surg Lasers Imaging. 2005;36(4):270-1.
2. Lima Filho AAS, Dantas AM, Sallum JMF, Ferreira Filho N, Marback RL. Fisiologia da retina e das vias ópticas. In: Conselho Brasileiro de Oftalmologia. Bases da oftalmologia. São Paulo: Cultura Médica; 2008. p.627-794. (Série Brasileira de Oftalmologia).
3. Peyman GA, Ganiban GJ. Delivery systems for intraocular routes. Adv Drug Deliv Rev. 1995;16(1):107-23.
4. Bourlais CL, Acar L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug delivery systems-recent advances. Prog Retin Eye Res. 1998;17(1):33-58. Review.
5. nd ed. New York: Saunders; 2002. p.143-52.
6. Geroski DH, Edelhauser HF. Drug delivery for posterior segment eye disease. Invest Ophthalmol Vis Sci. 2000;41(5):961-4.
7. Keller N, Tsao SW, Chandrasekaran K, Hatfield JM. Ocular kinetics of extended duration fluorometholone (0.1%) formulations vs ointment and aqueous suspension. Invest Ophthalmol Vis Sci. 1993;34(Suppl):1490-1.
8. Yalvac IS, Basci NE, Bozkurt A, Duman S. Penetration of topically applied ciprofloxacin and ofloxacin into the aqueous humor and vitreous. J Cataract Refract Surg. 2003;29(3):487-91.
9. Warren KA, Fox JE. Topical nepafenac as an alternative treatment for cystoid macular edema in steroid responsive patients. Retina. 2008;28(10):1427-34.
10. Geroski DH, Edelhauser HF. Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev. 2001;52(1):37-48. Review.
11. Okabe J, Kimura H, Kunou N, Okabe K, Kato A, Ogura Y. Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate. Invest Ophthalmol Vis Sci. 2003;44(2):740-4.
12. Kompella UB, Bandi N, Ayalasomayajula SP. Subconjunctival nano- and micro-particles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci. 2003;44(3):1192-201.
13. Ambati J, Adamis AP. Transscleral drug delivery to the retina and choroid. Prog Retin Eye Res. 2002;21(2):145-51. Review.
14. Weijtens O, Schoemaker RC, Lentjes EG, Romijn FP, Cohen AF, van Meurs JC. Dexamethasone concentration in the subretinal fluid after a subconjunctival injection, a peribulbar injection, or an oral dose. Ophthalmology. 2000;107(10):1932-8.
15. Ambati J, Canakis CS, Miller JW, Gragoudas ES, Edwards A, Weissgold DJ, et al. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci. 2000;41(5):1181-5.
16. Ambati J, Gragoudas ES, Miller JW, You TT, Miyamoto K, Delori FC, Adamis AP. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci. 2000;41(5):1186-91.
17. Kato A, Kimura H, Okabe K, Okabe J, Kunou N, Ogura Y. Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant. Invest Ophthalmol Vis Sci. 2004;45(1):238-44.
18. Rudnick DE, Noonan JS, Geroski DH, Prausnitz MR, Edelhauser HF. The effect of intraocular pressure on human and rabbit scleral permeability. Invest Ophthalmol Vis Sci. 1999;40(12):3054-8.
19. Peyman GA, Herbst R. Bacterial endophthalmitis. Treatment with intraocular injection of gentamicin and dexamethasone. Arch Ophthalmol. 1974;91(5):416-8.
20. Cochereau-Massin I, Lehoang P, Lautier-Frau M, Zazoun L, Marcel P, Robinet M, et al. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology. 1991;98(9): 1348-53; discussion 1353-5.
21. Aiello LP, Brucker AJ, Chang S, Cunningham ET Jr, D'Amico DJ, Flynn HW Jr, et al. Evolving guidelines for intravitreous injections. Retina. 2004; 24(5 Suppl):S3-19. Review.
22. Tano Y, Sugita G, Abrams G, Machemer R. Inhibition of intraocular proliferations with intravitreal corticosteroids. Am J Ophthalmol. 1980;89(1):131-6.
23. Mello-Filho PA, Guven D, Beeley NR, de Juan E Jr, Erickson SR. Helical intravitreal triamcinolone acetonide implant: a 6-month surgical feasibility study in rabbits. Ophthalmic Surg Lasers Imaging. 2009;40(2):160-8.
24. Rodrigues EB, Farah ME, Maia M, Penha FM, Regatieri C, Melo GB, et al. Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res. 2009; 28(2):117-44. Review.
25. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of prolife-rative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006; 26(3):275-8.
26. Dib E, Maia M, Longo-Maugeri IM, Martins MC, Mussalem JS, Squaiella CC, et al. Subretinal bevacizumab detection after intravitreous injection in rabbits. Invest Ophthalmol Vis Sci. 2008;49(3):1097-100.
27. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-31.
28. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neo-vascular age-related macular degeneration. N Engl J Med. 2006;355(14): 1432-44. Comment in: N Engl J Med. 2006;355(14):1409-12. N Engl J Med. 2007;356(7):748-9; author reply 749-50. N Engl J Med. 2007;356(7):747-8; author reply 749-50. N Engl J Med. 2006;355(14):1493-5.
29. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: a comprehensive review. Retina. 2004;24(5):676-98.
30. Akula SK, Ma PE, Peyman GA, Rahimy MH, Hyslop NE Jr, Janney A, Ashton P. Treatment of cytomegalovirus retinitis with intravitreal injection of liposome encapsulated ganciclovir in a patient with AIDS. Br J Ophthalmol. 1994;78(9):677-80.
31. Peyman GA, Charles HC, Liu KR, Khoobehi B, Niesman M. Intravitreal lipo-some-encapsulated drugs: a preliminary human report. Int Ophthalmol. 1988; 12(3):175-82.
32. Moritera T, Ogura Y, Honda Y, Wada R, Hyon SH, Ikada Y. Microspheres of biodegradable polymers as a drug-delivery system in the vitreous. Invest Ophthalmol Vis Sci. 1991;32(6):1785-90.
33. Musch DC, Martin DF, Gordon JF, Davis MD, Kuppermann BD. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. N Engl J Med. 1997;337(2):83-90.
34. Holekamp NM, Thomas MA, Pearson A. The safety profile of long-term, high-dose intraocular corticosteroid delivery. Am J Ophthalmol. 2005;139(3):421-8. Comment in: Am J Ophthalmol. 2005;139(3):533-5.
35. Jaffe GJ, Pearson PA, Ashton P. Dexamethasone sustained drug delivery implant for the treatment of severe uveitis. Retina. 2000;20(4):402-3.
36. Jaffe GJ, Ben-Num J, Guo H, Dunn JP, Ashton P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 2000; 107(11):2024-33.
37. Penha FM, Maia M, Farah ME, Dib E, Príncipe AH, Devin F, et al. Morphologic and clinical effects of subretinal injection of indocyanine green and infracyanine green in rabbits. J Ocul Pharmacol Ther. 2008;24(1):52-61.
38. Maia M, Haller JA, Pieramici DJ, Margalit E, de Juan E Jr, Farah ME, et al. Retinal pigment epithelial abnormalities after internal limiting membrane peeling guided by indocyanine green staining. Retina. 2004;24(1):157-60.
39. Rodrigues EB, Penha FM, Farah ME, de Paula Fiod Costa E, Maia M, Dib E, et al. Preclinical investigation of the retinal biocompatibility of six novel vital dyes for chromevitrectomy. Retina. 2009;29(4):497-510.
40. Rodrigues EB, Penha FM, Furlani B, Meyer CH, Maia M, Farah ME. Historical aspects and evolution of the application of vital dyes in vitreoretinal surgery and chromovitrectomy. Dev Ophthalmol. 2008;42:29-34.